Director, NIBR BD&L, Search and Evaluation, Novartis
Dr. Spier was educated in Biological Sciences at Oxford University, received his Ph.D. in molecular neuroscience from Cambridge University at the MRC-Laboratory of Molecular Biology and trained as a postdoc at The Scripps Research Institute (TSRI), La Jolla, CA. In 2001, Dr. Spier co-founded La Jolla based Allon Therapeutics, Inc. and led the peptide therapeutic neurodegenerative disease focused company as its President and CEO through two financing rounds and up to its entry onto the Toronto Stock Exchange. In 2004, Dr. Spier joined the Genomics Institute of the Novartis Research Foundation (GNF), as its Director of Business Development. In 2012 Dr. Spier was appointed Director of BD&L in NIBR, with responsibility for search and evaluation activities for the Cardiovascular, Metabolic and Diabetes (CVM), Global Discovery Chemistry (GDC), Chemical Biology and Therapeutics (CBT), GNF Systems and the Microbiome organizations of NIBR.